FI965153A - metalloproteinase - Google Patents
metalloproteinase Download PDFInfo
- Publication number
- FI965153A FI965153A FI965153A FI965153A FI965153A FI 965153 A FI965153 A FI 965153A FI 965153 A FI965153 A FI 965153A FI 965153 A FI965153 A FI 965153A FI 965153 A FI965153 A FI 965153A
- Authority
- FI
- Finland
- Prior art keywords
- compounds
- metalloproteinase
- inhibitors
- medicine
- processes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Abstract
Therapeutically active hydroxamic acid derivatives, processes for their preparation, pharmaceutical compositions containing them, and the use of such compounds in medicine. The compounds are inhibitors of metalloproteinases involved in tissue degradation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9412514A GB9412514D0 (en) | 1994-06-22 | 1994-06-22 | Metalloproteinase inhibitors |
GBGB9506107.3A GB9506107D0 (en) | 1995-03-24 | 1995-03-24 | Metalloproteinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
FI965153A0 FI965153A0 (en) | 1996-12-20 |
FI965153A true FI965153A (en) | 1996-12-20 |
Family
ID=26305102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI965153A FI965153A (en) | 1994-06-22 | 1996-12-20 | metalloproteinase |
Country Status (17)
Country | Link |
---|---|
US (4) | US6022898A (en) |
EP (2) | EP0766664B1 (en) |
JP (2) | JPH10501806A (en) |
CN (1) | CN1151157A (en) |
AT (2) | ATE182581T1 (en) |
AU (2) | AU695507B2 (en) |
CA (2) | CA2193692A1 (en) |
DE (2) | DE69516143T2 (en) |
DK (2) | DK0766665T3 (en) |
ES (2) | ES2133785T3 (en) |
FI (1) | FI965153A (en) |
GB (2) | GB2303850B (en) |
GR (2) | GR3031143T3 (en) |
NO (1) | NO965515L (en) |
NZ (2) | NZ288299A (en) |
PT (1) | PT766664E (en) |
WO (2) | WO1995035275A1 (en) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5646167A (en) * | 1993-01-06 | 1997-07-08 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamix acids |
US6380366B1 (en) * | 1994-04-28 | 2002-04-30 | Les Laboratoires Aeterna Inc. | Shark cartilage extract:process of making, methods of using and compositions thereof |
ES2133785T3 (en) * | 1994-06-22 | 1999-09-16 | British Biotech Pharm | METALOPROTEINASE INHIBITORS. |
US5817822A (en) * | 1994-06-24 | 1998-10-06 | Novartis Corporation | Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids |
US5863949A (en) * | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
KR980009238A (en) | 1995-07-28 | 1998-04-30 | 우에노 도시오 | Sulfonyl amino acid derivative |
ES2185750T3 (en) * | 1995-08-08 | 2003-05-01 | Ono Pharmaceutical Co | USEFUL HYDROXAMIC ACID DERIVATIVES FOR GELATINASA INHIBITION. |
US6207672B1 (en) † | 1995-11-13 | 2001-03-27 | Aventis Pharma Deutschland Gmbh | Cyclic and heterocyclic N-substituted α-iminohydroxamic and carboxyclic acids |
AU725831C (en) * | 1995-12-08 | 2002-10-17 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation |
US6500948B1 (en) | 1995-12-08 | 2002-12-31 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof |
TW453995B (en) * | 1995-12-15 | 2001-09-11 | Novartis Ag | Certain alpha-substituted arylsulfonamido acetohydroxamic acids |
US6919375B1 (en) | 1996-01-23 | 2005-07-19 | Shionogi & Co., Ltd. | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same |
JP3628335B2 (en) * | 1996-01-23 | 2005-03-09 | 塩野義製薬株式会社 | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same |
CA2242416C (en) * | 1996-01-23 | 2006-03-21 | Shionogi & Co., Ltd. | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same |
US5994351A (en) * | 1998-07-27 | 1999-11-30 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
FR2748026B1 (en) * | 1996-04-26 | 1998-06-05 | Adir | NOVEL METALLOPROTEASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
WO1997044315A1 (en) * | 1996-05-17 | 1997-11-27 | Warner-Lambert Company | Biphenylsulfonamide matrix metalloproteinase inhibitors |
JP2000516607A (en) * | 1996-08-16 | 2000-12-12 | ワーナー―ランバート・コンパニー | Butyrate matrix metalloproteinase inhibitor |
KR20000068248A (en) * | 1996-08-23 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | Arylsulfonylamino Hydroxamic Acid Derivatives |
CN1228773A (en) * | 1996-08-28 | 1999-09-15 | 普罗克特和甘保尔公司 | Heterocyclic metalloprotease inhibitors |
AU736238B2 (en) * | 1996-08-28 | 2001-07-26 | Procter & Gamble Company, The | Spirocyclic metalloprotease inhibitors |
CN1228771A (en) * | 1996-08-28 | 1999-09-15 | 普罗克特和甘保尔公司 | 1,3-diheterocyclic metalloprotease inhibitors |
CN1228780A (en) * | 1996-08-28 | 1999-09-15 | 普罗克特和甘保尔公司 | Phosphinic acid amides as matrix metalloprotease inhibitors |
DK0923561T3 (en) | 1996-08-28 | 2003-02-24 | Procter & Gamble | Heterocyclic metalloprotease inhibitors |
BR9712792A (en) * | 1996-08-28 | 1999-12-14 | Procter & Gamble | Bidentate metalloprotease inhibitors. |
US5929097A (en) * | 1996-10-16 | 1999-07-27 | American Cyanamid Company | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
US6228869B1 (en) | 1996-10-16 | 2001-05-08 | American Cyanamid Company | Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
US6548524B2 (en) | 1996-10-16 | 2003-04-15 | American Cyanamid Company | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
KR20000049196A (en) * | 1996-10-16 | 2000-07-25 | 윌리암 에이취 캘넌, 에곤 이 버그 | The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
US5977408A (en) * | 1996-10-16 | 1999-11-02 | American Cyanamid Company | Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
US5962481A (en) | 1996-10-16 | 1999-10-05 | American Cyanamid Company | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
CA2268418A1 (en) * | 1996-10-22 | 1998-04-30 | Pharmacia & Upjohn Company | .alpha.-amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors |
US6174915B1 (en) | 1997-03-25 | 2001-01-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
US6008243A (en) * | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
WO1998018754A1 (en) | 1996-10-28 | 1998-05-07 | Versicor, Inc. | Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof |
US6281245B1 (en) | 1996-10-28 | 2001-08-28 | Versicor, Inc. | Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof |
JP2001509810A (en) * | 1997-01-17 | 2001-07-24 | ファルマシア・アンド・アップジョン・カンパニー | Bis-sulfonamidohydroxamic acids as MMP inhibitors |
ZA98376B (en) * | 1997-01-23 | 1998-07-23 | Hoffmann La Roche | Sulfamide-metalloprotease inhibitors |
US6376506B1 (en) | 1997-01-23 | 2002-04-23 | Syntex (U.S.A.) Llc | Sulfamide-metalloprotease inhibitors |
US6197791B1 (en) | 1997-02-27 | 2001-03-06 | American Cyanamid Company | N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
US6172057B1 (en) | 1997-02-27 | 2001-01-09 | American Cyanamid Company | N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
US6451791B1 (en) | 1997-03-04 | 2002-09-17 | Monsanto Company | Amidoaromatic ring sulfonamide hydroxamic acid compounds |
GB9706255D0 (en) | 1997-03-26 | 1997-05-14 | Smithkline Beecham Plc | Novel compounds |
US5985900A (en) * | 1997-04-01 | 1999-11-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
WO1998043963A1 (en) * | 1997-04-01 | 1998-10-08 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
US5756545A (en) * | 1997-04-21 | 1998-05-26 | Warner-Lambert Company | Biphenysulfonamide matrix metal alloproteinase inhibitors |
AU7294098A (en) * | 1997-05-09 | 1998-11-27 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
ES2165640T3 (en) | 1997-05-09 | 2002-03-16 | Hoechst Ag | SUBSTITUTED DIAMINOCARBOXYL ACIDS. |
DE19719621A1 (en) | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarboxylic acids |
DE19719817A1 (en) * | 1997-05-13 | 1998-11-19 | Hoechst Ag | Substituted 6- and 7-aminotetrahydroisoquinoline carboxylic acids |
US6300514B1 (en) | 1997-06-25 | 2001-10-09 | Ono Pharmaceutical Co., Ltd. | Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient |
HUP0003851A3 (en) | 1997-07-22 | 2002-10-28 | Shionogi & Co | Pharmaceutical composition for the treatment or prevention of glomerulopathy |
IL134273A0 (en) | 1997-07-31 | 2001-04-30 | Procter & Gamble | Acyclic metalloprotease inhibitors |
PT895988E (en) * | 1997-08-08 | 2002-09-30 | Pfizer Prod Inc | ARYLSULPHONYLAMINO-HYDROXAMIC ACID DERIVATIVES |
US6130220A (en) * | 1997-10-16 | 2000-10-10 | Syntex (Usa) Inc. | Sulfamide-metalloprotease inhibitors |
GB9801690D0 (en) * | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
EP1918278A1 (en) | 1998-02-04 | 2008-05-07 | Novartis AG | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
US6410580B1 (en) | 1998-02-04 | 2002-06-25 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
KR20010041089A (en) * | 1998-02-19 | 2001-05-15 | 윌리암 에이취 캘넌, 에곤 이 버그 | N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
US6329418B1 (en) | 1998-04-14 | 2001-12-11 | The Procter & Gamble Company | Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
GB9810464D0 (en) * | 1998-05-16 | 1998-07-15 | British Biotech Pharm | Hydroxamic acid derivatives |
AU754050B2 (en) | 1998-07-16 | 2002-10-31 | Sanofi-Aventis Deutschland Gmbh | Phosphinous and phosphonic acid derivatives used as medicaments |
US6107337A (en) * | 1998-08-06 | 2000-08-22 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
DE19851184A1 (en) | 1998-11-06 | 2000-05-11 | Aventis Pharma Gmbh | N-arylsulfonylamino acid omega amides |
CN1178915C (en) | 1999-01-27 | 2004-12-08 | 惠氏控股有限公司 | Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (MMP) inhibitors/TNF-alpha converting enzyme (TACE) inhibitors |
US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
US6506936B1 (en) * | 1999-02-25 | 2003-01-14 | Fibrogen, Inc. | N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of c-proteinase and for treating or preventing disorders related to unregulated collagen production |
CN1362951A (en) | 1999-03-03 | 2002-08-07 | 宝洁公司 | Dihetero-substituted metalloprotease inhibitors |
BR0008716A (en) | 1999-03-03 | 2002-09-24 | Procter & Gamble | Metalloprotease inhibitors containing alkenyl or alkynyl |
DE60003863T2 (en) | 1999-03-31 | 2004-04-22 | Pfizer Products Inc., Groton | Dioxocyclopentylhydroxamsäure |
DE60023926T2 (en) | 1999-09-10 | 2006-07-20 | Merck & Co., Inc. | TYROSINE KINASE INHIBITORS |
US6696456B1 (en) * | 1999-10-14 | 2004-02-24 | The Procter & Gamble Company | Beta disubstituted metalloprotease inhibitors |
DK2014285T3 (en) | 1999-11-26 | 2010-06-28 | Shionogi & Co | NPYY5 receptor antagonists |
US6797820B2 (en) * | 1999-12-17 | 2004-09-28 | Vicuron Pharmaceuticals Inc. | Succinate compounds, compositions and methods of use and preparation |
US6465508B1 (en) | 2000-02-25 | 2002-10-15 | Wyeth | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors |
MXPA02009312A (en) * | 2000-03-21 | 2003-03-12 | Procter & Gamble | Heterocyclic side chain containing metalloprotease inhibitors. |
EP1265865A2 (en) * | 2000-03-21 | 2002-12-18 | The Procter & Gamble Company | Difluorobutyric acid derivatives and their use as metalloprotease inhibitors |
AR030196A1 (en) * | 2000-03-21 | 2003-08-13 | Procter & Gamble | COMPOUND CONTAINING CARBOCICLIC SIDE CHAIN, PHARMACEUTICAL COMPOSITION CONTAINING IT AND USE OF SUCH COMPOUND FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
IL151125A0 (en) | 2000-03-21 | 2003-04-10 | Procter & Gamble | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors |
US6495358B1 (en) | 2000-04-19 | 2002-12-17 | Wichita State University | Sulfamide and bis-sulfamide amino acid derivatives as inhibitors of proteolytic enzymes |
AU2001265182A1 (en) | 2000-05-30 | 2001-12-11 | Rafael Fridman | Inhibitors of matrix metalloproteinases |
US20040235896A1 (en) * | 2001-03-14 | 2004-11-25 | Fujimoto Roger Aki | Certain azacycloalkyl substituted acetic acid derivatives |
EP1392648A1 (en) | 2001-05-11 | 2004-03-03 | Guilford Pharmaceuticals Inc. | Hydroxamic acids and acyl hydroxamines as naaladase inhibitors |
ATE316088T1 (en) | 2001-06-22 | 2006-02-15 | Merck & Co Inc | TYROSINE KINASE INHIBITORS |
MXPA04004010A (en) | 2001-11-01 | 2004-07-23 | Wyeth Corp | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors. |
AU2003233154A1 (en) | 2002-06-10 | 2003-12-22 | Pfizer Inc. | Metabolites of prinomastat and their sythesis |
US6872724B2 (en) | 2002-07-24 | 2005-03-29 | Merck & Co., Inc. | Polymorphs with tyrosine kinase activity |
WO2005021489A2 (en) | 2002-12-23 | 2005-03-10 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
KR20050086949A (en) * | 2002-12-27 | 2005-08-30 | 안지오테크 인터내셔날 아게 | Compositions and methods of using collajolie |
JP2006516548A (en) | 2002-12-30 | 2006-07-06 | アンジオテック インターナショナル アクツィエン ゲゼルシャフト | Drug delivery from rapidly gelled polymer compositions |
US7576222B2 (en) * | 2004-12-28 | 2009-08-18 | Wyeth | Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase |
WO2006125208A1 (en) | 2005-05-19 | 2006-11-23 | Wayne State University | Inhibitors of matrix metalloproteinases |
US20110112076A1 (en) * | 2008-07-14 | 2011-05-12 | Mcquire Leslie Wighton | Selective hydroxamic acid based mmp-12 and mmp-13 inhibitors |
US8937151B2 (en) | 2010-03-04 | 2015-01-20 | University Of Notre Dame Du Lac | Gelatinase inhibitors and prodrugs |
WO2012038944A1 (en) | 2010-09-24 | 2012-03-29 | Ranbaxy Laboratories Limited | Matrix metalloproteinase inhibitors |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4077998A (en) * | 1975-10-28 | 1978-03-07 | Morton-Norwich Products, Inc. | Phthaloyl amino acid hydroxamic acids |
US4885027A (en) * | 1985-04-05 | 1989-12-05 | Chevron Research Company | Herbicidal arylmethylenesulfonamido-acetamide and thioacetamide derivatives |
DK77487A (en) * | 1986-03-11 | 1987-09-12 | Hoffmann La Roche | hydroxylamine |
WO1989005787A2 (en) * | 1987-12-18 | 1989-06-29 | Schering Corporation | Processes and compounds useful for resolving 1-methyl-3-phenylpropylamine |
GB8827305D0 (en) * | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
AU652596B2 (en) * | 1990-12-03 | 1994-09-01 | Celltech Limited | Peptidyl derivatives |
US5239113A (en) * | 1991-10-15 | 1993-08-24 | Monsanto Company | Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5552419A (en) * | 1993-01-06 | 1996-09-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
ES2133785T3 (en) * | 1994-06-22 | 1999-09-16 | British Biotech Pharm | METALOPROTEINASE INHIBITORS. |
US5817822A (en) * | 1994-06-24 | 1998-10-06 | Novartis Corporation | Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids |
WO1997044315A1 (en) * | 1996-05-17 | 1997-11-27 | Warner-Lambert Company | Biphenylsulfonamide matrix metalloproteinase inhibitors |
-
1995
- 1995-06-22 ES ES95922639T patent/ES2133785T3/en not_active Expired - Lifetime
- 1995-06-22 CN CN95193714A patent/CN1151157A/en active Pending
- 1995-06-22 DK DK95922639T patent/DK0766665T3/en active
- 1995-06-22 GB GB9623675A patent/GB2303850B/en not_active Expired - Fee Related
- 1995-06-22 DE DE69516143T patent/DE69516143T2/en not_active Expired - Fee Related
- 1995-06-22 PT PT95922638T patent/PT766664E/en unknown
- 1995-06-22 ES ES95922638T patent/ES2145913T3/en not_active Expired - Lifetime
- 1995-06-22 US US08/765,146 patent/US6022898A/en not_active Expired - Fee Related
- 1995-06-22 EP EP95922638A patent/EP0766664B1/en not_active Expired - Lifetime
- 1995-06-22 CA CA002193692A patent/CA2193692A1/en not_active Abandoned
- 1995-06-22 JP JP8501847A patent/JPH10501806A/en active Pending
- 1995-06-22 AT AT95922639T patent/ATE182581T1/en not_active IP Right Cessation
- 1995-06-22 CA CA002193691A patent/CA2193691A1/en not_active Abandoned
- 1995-06-22 NZ NZ288299A patent/NZ288299A/en unknown
- 1995-06-22 AU AU27465/95A patent/AU695507B2/en not_active Ceased
- 1995-06-22 NZ NZ288298A patent/NZ288298A/en unknown
- 1995-06-22 US US08/765,140 patent/US5962529A/en not_active Expired - Fee Related
- 1995-06-22 AT AT95922638T patent/ATE191468T1/en not_active IP Right Cessation
- 1995-06-22 AU AU27466/95A patent/AU690703B2/en not_active Ceased
- 1995-06-22 EP EP95922639A patent/EP0766665B1/en not_active Expired - Lifetime
- 1995-06-22 JP JP8501848A patent/JPH10507158A/en not_active Withdrawn
- 1995-06-22 GB GB9623809A patent/GB2303629B/en not_active Expired - Fee Related
- 1995-06-22 DE DE69511089T patent/DE69511089T2/en not_active Expired - Fee Related
- 1995-06-22 WO PCT/GB1995/001464 patent/WO1995035275A1/en active IP Right Grant
- 1995-06-22 WO PCT/GB1995/001465 patent/WO1995035276A1/en active IP Right Grant
- 1995-06-22 DK DK95922638T patent/DK0766664T3/en active
-
1996
- 1996-12-20 NO NO965515A patent/NO965515L/en unknown
- 1996-12-20 FI FI965153A patent/FI965153A/en unknown
-
1999
- 1999-02-03 US US09/243,130 patent/US6124332A/en not_active Expired - Fee Related
- 1999-06-30 US US09/343,087 patent/US6124329A/en not_active Expired - Fee Related
- 1999-09-02 GR GR990402229T patent/GR3031143T3/en unknown
-
2000
- 2000-05-18 GR GR20000401133T patent/GR3033446T3/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69516143T2 (en) | METALLOPROTEINASE INHIBITORS | |
SE9402431D0 (en) | New tablet formulation | |
BR9406363A (en) | Pharmaceutical composition process for the preparation of the same use and process for the treatment of diseases related to gastric acid | |
NO20051966L (en) | New pyrimidinamide derivatives and their use | |
UA50719C2 (en) | Precursor for therapy of cancer and inflammation | |
TR199801184T2 (en) | New compounds with analgesic action. | |
ATE286395T1 (en) | ANTITHRBOTIC AGENTS | |
FI932654A0 (en) | Hydroxamsyraderivat, som hindrar lipoxigenas | |
HUP0203321A2 (en) | 6-methoxy-2-naphthylacetic acid prodrugs compositions for treating inflammation | |
ES2194899T3 (en) | PHARMACEUTICAL COMPOSITION FOR SYSTEMIC TRANSDERMAL ADMINISTRATION OF THE MORFINA-6-GLUCURONIDO ACTIVE PRINCIPLE. | |
TR200003451T2 (en) | Pyrimidine-Aminomethyl-Pyridine Derivatives, Their Preparation and Their Use in the Control of Helicobacter Bacteria | |
DE69910787D1 (en) | NEW, ACTIVE PHARMACEUTICAL CONNECTION | |
TR200100906T2 (en) | Benzamide derivatives as thrombin inhibitors | |
NO20001846L (en) | New pharmaceutically active compounds, their preparation and use as ECE inhibitors | |
ATE268768T1 (en) | ANTITHROMBOTIC AGENTS | |
ATE109981T1 (en) | THERAPEUTIC REMEDIES. | |
JO1881B1 (en) | Multiple unit tableted dosage from ii | |
IT1255678B (en) | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF PARATORMONE, ITS BIOLOGICALLY ACTIVE FRAGMENTS OR RECTAL RELATED PEPTIDES. | |
MX9503130A (en) | Metaloproteinase inhibitors, process for their preparation and pharmaceutical or veterinarian compositions containing them. |